Oxitropium bromide (Ba253BINEB) vs Umeclidinium
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Asthma
Shared mechanism: Muscarinic acetylcholine receptor (M3) · full Asthma pipeline
Oxitropium bromide (Ba253BINEB)
Developed by Boehringer Ingelheim
NCT02182661 · Phase 3 · completed
The study was an open-label, single-arm trial of 88 participants with no randomization or comparator group. Its primary outcomes were safety measures, but no results were posted, so there is no reported primary-endpoint comparison to assess.
No aligned efficacy figure on record for this race.
Umeclidinium · Incruse Ellipta
Marketed by GlaxoSmithKline
NCT01573624 · Phase 2 · completed
The study randomized 421 participants to three 14-day treatment periods and kept participants and investigators blinded, with active comparator arms. Its primary outcomes were lung-function measures rather than hard clinical outcomes, and the results were mixed: trough FEV1 was significantly higher with the 125- and 250-mcg UMEC doses but not with the lower doses.
Reported efficacy
Model Predicted Change From Baseline Trough Force Expiratory Volume in 1 Second (FEV1) (Baseline (Day 1) and Day 15 of each treatment period); Percentage of Chance That FF 100 mcg Alone Corrected Change From Baseline FEV1 Response Would Exceed a Target Response by Dose of UMEC Combined With FF 100 mcg (Baseline (Day 1) and Day 15 of each treatment period); Mean Change From Baseline in Trough FEV1 on Day 15 of Each of the 3 Treatment Periods (Baseline (Day 1) and Day 15 of each treatment period): Model Predicted Change From Baseline Trough Force Expiratory Volume in 1 Second (FEV1) (Baseline (Day 1) and Day 15 of each treatment period): FF 100 mcg + UMEC 15.6 mcg 0.026 Litres (L) (95% CI -0.0098 to 0.0611) | FF 100 mcg + UMEC 31.25 mcg 0.032 Litres (L) (95% CI -0.0036 to 0.0679) | FF 100 mcg + UMEC 62.5 mcg 0.0385 Litres (L) (95% CI -0.0011 to 0.0745) | FF 100 mcg + UMEC 125 mcg 0.0444 Litres (L) (95% CI 0.0067 to 0.0813) | FF 100 mcg + UMEC 250 mcg 0.051 Litres (L) (95% CI 0.0139 to 0.0873) (mixed)
Result source: NCT01573624
Results for Asthma
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Oxitropium bromide (Ba253BINEB) | Umeclidinium |
|---|---|---|
| Severe exacerbations, annualised rate | —Not posted · NCT02182661 | —Trial running · NCT04651777 |
| Trough FEV1, change | —Not posted · NCT02182661 | 0.3 vs 0.1+0.2 vs placeboNCT0301206117 other results
|
| ACQ-5, change | —Not posted · NCT02182661 | —Trial running · NCT04651777 |
| OCS dose reduction | —Not posted · NCT02182661 | —Trial running · NCT04651777 |
Severe exacerbations, annualised rate
- Oxitropium bromide (Ba253BINEB)
- —Not posted · NCT02182661
- Umeclidinium
- —Trial running · NCT04651777
Trough FEV1, change
- Oxitropium bromide (Ba253BINEB)
- —Not posted · NCT02182661
- Umeclidinium
- 0.3 vs 0.1+0.2 vs placeboNCT03012061
17 other results
- 0.1 vs 0.0 NCT01641692
- 0.1 vs 0.0 NCT01641692
- 0.1 vs 0.0 NCT01641692
- 0.1 vs 0.0 NCT01641692
- 0.3 vs 0.1 NCT03012061
- 0.1 vs 0.0 NCT01641692
- 0.1 vs 0.0 NCT01641692
- 0.1 vs 0.0 NCT01641692
- 0.1 vs 0.1 NCT02164539
- 0.1 vs 0.2 NCT01573624
- 0.2 vs 0.2 NCT01573624
- 0.1 vs 0.2 NCT01573624
- 0.2 vs 0.2 NCT01573624
- 0.2 vs 0.2 NCT01573624
- 0.2 vs 0.1 NCT02164539
- 0.1 vs 0.1 NCT02164539
- 0.2 vs 0.1 NCT02164539
ACQ-5, change
- Oxitropium bromide (Ba253BINEB)
- —Not posted · NCT02182661
- Umeclidinium
- —Trial running · NCT04651777
OCS dose reduction
- Oxitropium bromide (Ba253BINEB)
- —Not posted · NCT02182661
- Umeclidinium
- —Trial running · NCT04651777
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Oxitropium bromide (Ba253BINEB): no structured comparison results are available for Asthma.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Oxitropium bromide (Ba253BINEB): 0 of 4 rows · Umeclidinium: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Umeclidinium |
|---|---|
| Dropout rate | —100 mcg + 125 mcga NCT01573624 · Phase 2 · combination · Asthma · phase 2 show 19 more results—100 mcg + 15.6 mcg NCT01573624 · Phase 2 · combination · Asthma · phase 2 —100 mcg + 250 mcg NCT01573624 · Phase 2 · combination · Asthma · phase 2 —100 mcg + 31.25 mcg NCT01573624 · Phase 2 · combination · Asthma · phase 2 —100 mcg + 62.5 mcg NCT01573624 · Phase 2 · combination · Asthma · phase 2 5.9%31.25 µg BID NCT01641692 · Phase 2 · combination · Asthma · phase 2 2%31.25 µg QD NCT01641692 · Phase 2 · combination · Asthma · phase 2 5.1%250 µg QD NCT01641692 · Phase 2 · combination · Asthma · phase 2 9.3%125 µg QD NCT01641692 · Phase 2 · combination · Asthma · phase 2 0%62.5 µg QD NCT01641692 · Phase 2 · combination · Asthma · phase 2 —31.5 µg QD NCT01641692 · Phase 2 · combination · Asthma · phase 2 0%15.6 µg BID NCT01641692 · Phase 2 · combination · Asthma · phase 2 0%15.6 µg QD NCT01641692 · Phase 2 · combination · Asthma · phase 2 6.5%31.25 mcg QD NCT03012061 · Phase 2 · registry result, not featured evidence · background therapy 5.8%62.5 mcg QD NCT03012061 · Phase 2 · registry result, not featured evidence · background therapy 3.5%100/250 µg NCT02164539 · Phase 2 · registry result, not featured evidence · combination 4.3%100/125 µg NCT02164539 · Phase 2 · registry result, not featured evidence · combination 0%100/15.6 µg NCT02164539 · Phase 2 · registry result, not featured evidence · combination 2.5%100/62.5 µg NCT02164539 · Phase 2 · registry result, not featured evidence · combination —100/250/25 µg NCT02164539 · Phase 2 · registry result, not featured evidence · combination |
| Discontinued due to AEs | —100 mcg + 125 mcga NCT01573624 · Phase 2 · combination · Asthma · phase 2 show 19 more results—100 mcg + 15.6 mcg NCT01573624 · Phase 2 · combination · Asthma · phase 2 —100 mcg + 250 mcg NCT01573624 · Phase 2 · combination · Asthma · phase 2 —100 mcg + 31.25 mcg NCT01573624 · Phase 2 · combination · Asthma · phase 2 —100 mcg + 62.5 mcg NCT01573624 · Phase 2 · combination · Asthma · phase 2 0%31.25 µg BID NCT01641692 · Phase 2 · combination · Asthma · phase 2 0%31.25 µg QD NCT01641692 · Phase 2 · combination · Asthma · phase 2 0%250 µg QD NCT01641692 · Phase 2 · combination · Asthma · phase 2 0%125 µg QD NCT01641692 · Phase 2 · combination · Asthma · phase 2 0%62.5 µg QD NCT01641692 · Phase 2 · combination · Asthma · phase 2 —31.5 µg QD NCT01641692 · Phase 2 · combination · Asthma · phase 2 0%15.6 µg BID NCT01641692 · Phase 2 · combination · Asthma · phase 2 0%15.6 µg QD NCT01641692 · Phase 2 · combination · Asthma · phase 2 0%31.25 mcg QD NCT03012061 · Phase 2 · registry result, not featured evidence · background therapy 0%62.5 mcg QD NCT03012061 · Phase 2 · registry result, not featured evidence · background therapy —100/250 µg NCT02164539 · Phase 2 · registry result, not featured evidence · combination —100/125 µg NCT02164539 · Phase 2 · registry result, not featured evidence · combination —100/15.6 µg NCT02164539 · Phase 2 · registry result, not featured evidence · combination —100/62.5 µg NCT02164539 · Phase 2 · registry result, not featured evidence · combination —100/250/25 µg NCT02164539 · Phase 2 · registry result, not featured evidence · combination |
| Serious AEs | 0%100 mcg + 125 mcga NCT01573624 · Phase 2 · combination · Asthma · phase 2 show 19 more results0%100 mcg + 15.6 mcg NCT01573624 · Phase 2 · combination · Asthma · phase 2 0%100 mcg + 250 mcg NCT01573624 · Phase 2 · combination · Asthma · phase 2 0.6%100 mcg + 31.25 mcg NCT01573624 · Phase 2 · combination · Asthma · phase 2 0%100 mcg + 62.5 mcg NCT01573624 · Phase 2 · combination · Asthma · phase 2 0%31.25 µg BID NCT01641692 · Phase 2 · combination · Asthma · phase 2 —31.25 µg QD NCT01641692 · Phase 2 · combination · Asthma · phase 2 0.7%250 µg QD NCT01641692 · Phase 2 · combination · Asthma · phase 2 0%125 µg QD NCT01641692 · Phase 2 · combination · Asthma · phase 2 0%62.5 µg QD NCT01641692 · Phase 2 · combination · Asthma · phase 2 0%31.5 µg QD NCT01641692 · Phase 2 · combination · Asthma · phase 2 0%15.6 µg BID NCT01641692 · Phase 2 · combination · Asthma · phase 2 0%15.6 µg QD NCT01641692 · Phase 2 · combination · Asthma · phase 2 2.9%31.25 mcg QD NCT03012061 · Phase 2 · registry result, not featured evidence · background therapy 2.2%62.5 mcg QD NCT03012061 · Phase 2 · registry result, not featured evidence · background therapy 0.5%100/250 µg NCT02164539 · Phase 2 · registry result, not featured evidence · combination 0%100/125 µg NCT02164539 · Phase 2 · registry result, not featured evidence · combination 0%100/15.6 µg NCT02164539 · Phase 2 · registry result, not featured evidence · combination 0%100/62.5 µg NCT02164539 · Phase 2 · registry result, not featured evidence · combination 0%100/250/25 µg NCT02164539 · Phase 2 · registry result, not featured evidence · combination |
| Most frequent reported AEs | show 18 more results31.25 µg BID headache 4.5% (placebo 1.6%) nasopharyngitis 1.5% (placebo 0.8%) pharyngitis 0% (placebo 0.8%) NCT01641692 · Phase 2 · combination · Asthma · phase 2 250 µg QD headache 4.4% (placebo 1.6%) product taste abnormal 3.7% (placebo 0%) nasopharyngitis 0.7% (placebo 0.8%) NCT01641692 · Phase 2 · combination · Asthma · phase 2 125 µg QD headache 3.1% (placebo 1.6%) product taste abnormal 3.1% (placebo 0%) nasopharyngitis 2.3% (placebo 0.8%) NCT01641692 · Phase 2 · combination · Asthma · phase 2 62.5 µg QD headache 3.8% (placebo 1.6%) pharyngitis 3.8% (placebo 0.8%) nasopharyngitis 0.8% (placebo 0.8%) NCT01641692 · Phase 2 · combination · Asthma · phase 2 31.5 µg QD headache 2.9% (placebo 1.6%) product taste abnormal 1.4% (placebo 0%) pharyngitis 0.7% (placebo 0.8%) NCT01641692 · Phase 2 · combination · Asthma · phase 2 15.6 µg BID nasopharyngitis 3.2% (placebo 0.8%) headache 1.6% (placebo 1.6%) pharyngitis 0.8% (placebo 0.8%) NCT01641692 · Phase 2 · combination · Asthma · phase 2 15.6 µg QD headache 3.8% (placebo 1.6%) nasopharyngitis 2.3% (placebo 0.8%) pharyngitis 0% (placebo 0.8%) NCT01641692 · Phase 2 · combination · Asthma · phase 2 31.25 mcg QD nasopharyngitis 10.1% (placebo 11.9%) headache 6.5% (placebo 7.7%) upper respiratory tract infection 5.8% (placebo 2.1%) NCT03012061 · Phase 2 · registry result, not featured evidence · background therapy 62.5 mcg QD nasopharyngitis 9.4% (placebo 11.9%) headache 8.6% (placebo 7.7%) upper respiratory tract infection 4.3% (placebo 2.1%) NCT03012061 · Phase 2 · registry result, not featured evidence · background therapy 100/250 µg nasopharyngitis 1.9% toothache 0.5% dysphonia 0% NCT02164539 · Phase 2 · registry result, not featured evidence · combination 100/125 µg dysphonia 6.5% nasopharyngitis 4.3% toothache 0% NCT02164539 · Phase 2 · registry result, not featured evidence · combination 100/15.6 µg nasopharyngitis 7.1% toothache 7.1% dysphonia 0% NCT02164539 · Phase 2 · registry result, not featured evidence · combination 100/62.5 µg nasopharyngitis 5% dysphonia 2.5% toothache 2.5% NCT02164539 · Phase 2 · registry result, not featured evidence · combination 100/250/25 µg dysphonia 0% nasopharyngitis 0% toothache 0% NCT02164539 · Phase 2 · registry result, not featured evidence · combination |
Notes
- aPopulation comparability has not been reviewed for 7 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Umeclidinium
show 4 more results
show 17 more results
show 4 more results
show 4 more results
show 6 more results
show 6 more results
show 5 more results
show 3 more results
show 3 more results
show 3 more results
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Oxitropium bromide (Ba253BINEB)'s landscape · Umeclidinium's landscape